From my multiple vantage points as a scientist, academician and founder of NeuroCog Trials, Inc., I see this as a pivotal time in the field of neurocognition. The domains of neurocognition are increasingly being assessed in clinical drug trials, even beyond traditional CNS related disorders; numerous studies point to neurocognition as a significant corollary with overall quality of life; and a growing body of research is pointing to its importance as not only an outcome measure but also a prognostic tool.

This is also a pivotal time for NeuroCog, which I founded six years ago as a way to extend the wealth of knowledge generated from academic science and innovation to a broader community. As the global science, medical and pharmaceutical communities become more attuned to the growing importance of cognitive testing, we stand ready to design and manage the execution of clinical and scientific trials in ways that honor our academic standards and our commitment to providing each and every client with the absolute best in cognition testing.

I take great pride in the quality of our products and services at NeuroCog and will continue to ensure we are the premier resource for supporting all stages of clinical trials from design through study implementation and interpretation of results – with best-in-class customized solutions for every client, the gold standard in instruments and products, the most thoroughly trained testers in the industry and a company-wide obsession to precision and detail across every single aspect of what we do.

I am confident that the information within this site demonstrates our commitment to providing the highest quality neurocognitive testing services anywhere in the world. And if you don’t find the proof you need here, please don’t hesitate to contact us.

We look forward to meeting the new and growing demands of this exciting field together, and continuing to bring to you the best that our depth of experience in industry and academia has to offer.

Richard Keefe, PhD, Founder and CEO